Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Theraphy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial - 09/08/11
, Yunmei Wang, PhD f, 1, Kevin Croce, MD, PhD b, Masashi Sakuma, MD f, Marc S. Sabatine, MD, MPH a, b, d, e, Huiyun Gao, MD f, Aruna D. Pradhan, MD c, Aileen M. Healy, PhD f, Jacki Buros, BS a, Carolyn H. McCabe, BS a, Peter Libby, MD b, d, e, Christopher P. Cannon, MD a, b, e, Eugene Braunwald, MD a, b, e, Daniel I. Simon, MD f, ⁎ Résumé |
Background |
Using a transcriptional profiling approach, we recently identified myeloid-related protein 8/14 (MRP-8/14) to be expressed by platelets during acute myocardial infarction (MI). Elevated concentrations of MRP-8/14 are associated with a higher risk for future cardiovascular events in apparently healthy individuals but have not been assessed with respect to prognosis in patients with acute coronary syndrome.
Methods |
We performed a nested case-control study (n = 237 case-control pairs) among patients enrolled in the Pravastatin or Atorvastatin Evaluation and Infection Theraphy: Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial (mean follow-up 24 months) to investigate the risk of cardiovascular death or MI associated with MRP-8/14 measured at 30 days after an acute coronary syndrome.
Results |
Patients with cardiovascular death or MI after 30 days (cases) had higher median [25th, 75th percentile] MRP-8/14 levels than patients who remained free of recurrent events (5.6 [2.8, 13.5] mg/L vs 4.0 [1.9, 10.1] mg/L, P = .020). The risk of a recurrent cardiovascular event increased with each increasing quartile of MRP-8/14 (P-trend = 0.007) such that patients with the highest levels had a 2.0-fold increased odds (95% CI 1.1-3.6, P = .029) of a recurrent event after adjusting for standard risk indicators, randomized treatment, and C-reactive protein. Patients with elevated levels of MRP-8/14 and high-sensitivity C-reactive protein showed significantly increased risk of cardiovascular death or MI compared with patients with the lowest levels of both markers (adjusted odds ratio 2.1, 95% CI 1.2-3.8).
Conclusions |
Myeloid-related protein 8/14 may be a useful biomarker of platelet and inflammatory disease activity in atherothrombosis and may serve as a novel target for therapeutic intervention.
Le texte complet de cet article est disponible en PDF.Plan
| The PROVE IT-TIMI 22 trial was supported by Bristol-Myers Squibb, Princeton, NJ. Drs Morrow and Sabatine are supported in part by National Institutes of Health grant U01 HL083-1341. This work was also supported in part by grants from the National Institutes of Health (HL57506 and HL60942 to Dr Simon). Dr Pradhan is supported by funding from the National Institutes of Health (HL082740). Dr Libby is supported by research funds from the Leducq Foundation (Paris, France), the Doris Duke Foundation (New York, NY), and the Donald W. Reynolds Foundation (Las Vegas, NV). |
Vol 155 - N° 1
P. null - janvier 2008 Retour au numéro
Article précédent
- Comparing invasive and noninvasive management strategies for acute myocardial infarction using administrative databases
- Louise Pilote, Christine A. Beck, Mark J. Eisenberg, Karin Humphries, Lawrence Joseph, John R. Penrod, Jack V. Tu
- Inflammatory responses after intracoronary injection of autologous mononuclear bone marrow cells in patients with acute myocardial infarction
- Svein Solheim, Ingebjørg Seljeflot, Ketil Lunde, Pål Aukrust, Arne Yndestad, Haakon Kiil Grøgaard, Svend Aakhus, Kolbjørn Forfang, Harald Arnesen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?